0.3143
price down icon4.12%   -0.0111
 
loading
Fibrogen Inc stock is traded at $0.3143, with a volume of 748.91K. It is down -4.12% in the last 24 hours and down -14.92% over the past month. FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.
See More
Previous Close:
$0.3254
Open:
$0.3254
24h Volume:
748.91K
Relative Volume:
0.62
Market Cap:
$31.91M
Revenue:
$147.75M
Net Income/Loss:
$-284.23M
P/E Ratio:
-0.0927
EPS:
-3.39
Net Cash Flow:
$-317.54M
1W Performance:
+1.89%
1M Performance:
-14.92%
6M Performance:
-72.63%
1Y Performance:
-51.81%
1-Day Range:
Value
$0.3051
$0.3254
1-Week Range:
Value
$0.29
$0.3352
52-Week Range:
Value
$0.29
$2.93

Fibrogen Inc Stock (FGEN) Company Profile

Name
Name
Fibrogen Inc
Name
Phone
415-978-1200
Name
Address
409 ILLINOIS STREET, SAN FRANCISCO, CA
Name
Employee
486
Name
Twitter
@FibroGenInc
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
FGEN's Discussions on Twitter

Fibrogen Inc Stock (FGEN) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-31-23 Upgrade William Blair Mkt Perform → Outperform
Jan-26-23 Upgrade Raymond James Mkt Perform → Outperform
Jan-05-23 Upgrade BofA Securities Neutral → Buy
Sep-22-21 Downgrade Goldman Neutral → Sell
Aug-20-21 Upgrade Raymond James Underperform → Mkt Perform
Jul-16-21 Downgrade BofA Securities Buy → Neutral
Jul-16-21 Downgrade Stifel Buy → Hold
Apr-07-21 Downgrade H.C. Wainwright Buy → Neutral
Apr-07-21 Downgrade Mizuho Buy → Neutral
Mar-31-21 Upgrade BofA Securities Neutral → Buy
Mar-02-21 Downgrade Jefferies Buy → Hold
Feb-01-21 Initiated H.C. Wainwright Buy
Oct-26-20 Initiated Raymond James Underperform
Jul-10-20 Resumed Stifel Buy
May-01-20 Initiated Cowen Market Perform
Apr-27-20 Initiated BofA/Merrill Neutral
May-29-19 Resumed Goldman Neutral
May-10-19 Downgrade William Blair Outperform → Mkt Perform
Apr-12-19 Initiated Piper Jaffray Neutral
Feb-11-19 Resumed Stifel Buy
Dec-19-18 Upgrade Citigroup Neutral → Buy
Aug-08-17 Reiterated Leerink Partners Outperform
Aug-08-17 Reiterated Stifel Buy
Jul-21-17 Downgrade Goldman Buy → Neutral
Jul-11-17 Initiated Jefferies Buy
Feb-11-16 Upgrade Credit Suisse Neutral → Outperform
Jan-21-16 Initiated Credit Suisse Neutral
Dec-04-15 Initiated Citigroup Buy
Sep-23-15 Initiated Lake Street Hold
Jul-29-15 Initiated Citigroup Buy
Jul-20-15 Upgrade Goldman Neutral → Buy
Dec-09-14 Initiated Stifel Buy
View All

Fibrogen Inc Stock (FGEN) Latest News

pulisher
Nov 04, 2024

FibroGen to Report Third Quarter 2024 Financial Results - GlobeNewswire

Nov 04, 2024
pulisher
Oct 31, 2024

Metrics That Matter About FibroGen Inc (NASDAQ: FGEN) - Stocks Register

Oct 31, 2024
pulisher
Oct 29, 2024

FGEN stock touches 52-week low at $0.3 amid market challenges - Investing.com Australia

Oct 29, 2024
pulisher
Oct 29, 2024

Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 26% Pounding - Simply Wall St

Oct 29, 2024
pulisher
Oct 29, 2024

FibroGen (NASDAQ:FGEN) Coverage Initiated by Analysts at StockNews.com - Defense World

Oct 29, 2024
pulisher
Oct 28, 2024

FGEN stock touches 52-week low at $0.3 amid market challenges By Investing.com - Investing.com South Africa

Oct 28, 2024
pulisher
Oct 21, 2024

FibroGen (NASDAQ:FGEN) Research Coverage Started at StockNews.com - Defense World

Oct 21, 2024
pulisher
Oct 16, 2024

The growth track for FibroGen Inc (FGEN) has changed recently - SETE News

Oct 16, 2024
pulisher
Oct 15, 2024

Should investors be concerned about FibroGen Inc (FGEN)? - US Post News

Oct 15, 2024
pulisher
Oct 15, 2024

Cubist Systematic Strategies LLC Has $256,000 Stock Holdings in FibroGen, Inc. (NASDAQ:FGEN) - Defense World

Oct 15, 2024
pulisher
Oct 14, 2024

Market Watch: FibroGen Inc (FGEN)’s Noteworthy Gain, Closing at 0.36 - The Dwinnex

Oct 14, 2024
pulisher
Oct 14, 2024

Pulmonary Fibrosis Drug Market Size & Analysis By 2024 -2034 -Boehringer Ingelheim, Roche, FibroGen, Inc., Merck & Co., – IndiaPolitics.com - IndiaPolitics.com

Oct 14, 2024
pulisher
Oct 12, 2024

Sei Investments Co. Purchases 41,442 Shares of FibroGen, Inc. (NASDAQ:FGEN) - Defense World

Oct 12, 2024
pulisher
Oct 12, 2024

Financial Review: FibroGen (NASDAQ:FGEN) and Oncotelic Therapeutics (OTCMKTS:OTLC) - Defense World

Oct 12, 2024
pulisher
Oct 11, 2024

FibroGen's US$6.2m Market Cap Fall Books Insider Losses - Simply Wall St

Oct 11, 2024
pulisher
Oct 10, 2024

FibroGen Inc [FGEN] Chief Medical Officer makes an insider acquire of 22,123 shares worth 25,884. - Knox Daily

Oct 10, 2024
pulisher
Oct 09, 2024

FibroGen Inc (FGEN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Shifts - Yahoo Finance

Oct 09, 2024
pulisher
Oct 09, 2024

Investors in cash trouble should check out FibroGen Inc (FGEN) - SETE News

Oct 09, 2024
pulisher
Oct 08, 2024

FGEN stock touches 52-week low at $0.33 amid market challenges By Investing.com - Investing.com South Africa

Oct 08, 2024
pulisher
Oct 08, 2024

FGEN stock touches 52-week low at $0.33 amid market challenges - Investing.com Australia

Oct 08, 2024
pulisher
Oct 08, 2024

A year in review: FibroGen Inc (FGEN)’s performance in the last year - US Post News

Oct 08, 2024
pulisher
Oct 07, 2024

Trading Day Triumph: FibroGen Inc (FGEN) Ends at 0.37, a -8.07 Surge/Plunge - The Dwinnex

Oct 07, 2024
pulisher
Oct 07, 2024

FibroGen Inc Inc. (FGEN) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle

Oct 07, 2024
pulisher
Oct 07, 2024

Investing in FibroGen Inc (FGEN): What You Must Know - Knox Daily

Oct 07, 2024
pulisher
Oct 05, 2024

StockNews.com Initiates Coverage on FibroGen (NASDAQ:FGEN) - Defense World

Oct 05, 2024
pulisher
Oct 04, 2024

FibroGen will pay $10M to exit HQ lease in SF’s Mission Bay - The Real Deal

Oct 04, 2024
pulisher
Oct 03, 2024

FibroGen Suit Alleging Disclosure Failures Tossed In Del. - Law360

Oct 03, 2024
pulisher
Oct 03, 2024

FibroGen to exit Mission Bay lease earlySan Francisco Business Times - The Business Journals

Oct 03, 2024
pulisher
Oct 03, 2024

FibroGen Cuts Costs by Terminating San Francisco Lease Early - TipRanks

Oct 03, 2024
pulisher
Oct 03, 2024

FibroGen Board Beats Lawsuit Over Failed AstraZeneca Partnership - Bloomberg Law

Oct 03, 2024
pulisher
Oct 03, 2024

Point72 DIFC Ltd Acquires 45,990 Shares of FibroGen, Inc. (NASDAQ:FGEN) - Defense World

Oct 03, 2024
pulisher
Oct 03, 2024

Stocks of FibroGen Inc (FGEN) are poised to climb above their peers - SETE News

Oct 03, 2024
pulisher
Oct 01, 2024

FibroGen Inc (FGEN) stock: A year of ups and downs - US Post News

Oct 01, 2024
pulisher
Sep 30, 2024

Doheny Asset Management CA Buys New Shares in FibroGen, Inc. (NASDAQ:FGEN) - Defense World

Sep 30, 2024
pulisher
Sep 29, 2024

Point72 DIFC Ltd Boosts Stake in FibroGen, Inc. (NASDAQ:FGEN) - Defense World

Sep 29, 2024
pulisher
Sep 26, 2024

475,716 Shares in FibroGen, Inc. (NASDAQ:FGEN) Purchased by XTX Topco Ltd - Defense World

Sep 26, 2024
pulisher
Sep 23, 2024

FibroGen Inc [FGEN] Investment Appeal on the Rise - Knox Daily

Sep 23, 2024
pulisher
Sep 23, 2024

Market Insights: FibroGen Inc (FGEN)’s Notable Drop of -1.78, Closing at 0.41 - The Dwinnex

Sep 23, 2024
pulisher
Sep 23, 2024

Is FibroGen Inc (FGEN) a threat to investors? - US Post News

Sep 23, 2024
pulisher
Sep 17, 2024

FibroGen faces potential Nasdaq delisting over share price - Investing.com India

Sep 17, 2024
pulisher
Sep 17, 2024

FibroGen faces potential Nasdaq delisting over share price By Investing.com - Investing.com Australia

Sep 17, 2024
pulisher
Sep 16, 2024

Investing in FibroGen Inc (FGEN) might be a great opportunity, but the stock is a bit overvalued - US Post News

Sep 16, 2024
pulisher
Sep 16, 2024

FGEN (FibroGen Inc) may reap gains as insiders became active recently - Knox Daily

Sep 16, 2024
pulisher
Sep 14, 2024

Acadian Asset Management LLC Acquires 860,854 Shares of FibroGen, Inc. (NASDAQ:FGEN) - Defense World

Sep 14, 2024
pulisher
Sep 13, 2024

FibroGen Announces Board Member Resignations and Committee Appointments - TipRanks

Sep 13, 2024
pulisher
Sep 11, 2024

FibroGen (NASDAQ:FGEN) Now Covered by StockNews.com - Defense World

Sep 11, 2024
pulisher
Sep 10, 2024

FibroGen announces executive departures amid cost cuts By Investing.com - Investing.com Australia

Sep 10, 2024
pulisher
Sep 09, 2024

FibroGen announces executive departures amid cost cuts - Investing.com

Sep 09, 2024
pulisher
Sep 08, 2024

FibroGen CFO, CMO to leave company by year's end - MSN

Sep 08, 2024
pulisher
Sep 07, 2024

FibroGen Executives Depart Amid U.S. Operations Overhaul - TipRanks

Sep 07, 2024
pulisher
Sep 06, 2024

Fibrogen, Inc. Announces Termination of Juan Graham as Chief Financial Officer, Effective December 15, 2024 - Marketscreener.com

Sep 06, 2024

Fibrogen Inc Stock (FGEN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Fibrogen Inc Stock (FGEN) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Wettig Thane
CEO
Mar 07 '24
Buy
1.91
50,000
95,470
470,178
$20.30
price up icon 1.75%
$75.59
price down icon 0.20%
$374.10
price down icon 0.29%
$52.67
price down icon 0.85%
$207.67
price up icon 0.20%
$108.59
price up icon 0.02%
Cap:     |  Volume (24h):